Ivor Percent, MD
Basic profileIvor Percent is an Oncology physician affiliated with Florida Cancer Specialists & Research Institute. OpenAlex indexes 53 publications with 2,724 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
83 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GenentechProgram year20259 paymentsResearch$40,578
- Bristol Myers SquibbProgram year20251 paymentResearch$33,530
- GenmabProgram year202520 paymentsResearch$30,657
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46%PD-1 inhibitor12.4%Pembrolizumab58%Nivolumab42%Part B, office-administered≥25 patientsLeukocyte Growth Factor11.4%Filgrastim87%Eflapegrastim-xnst13%Part B, office-administered≥14 patients+ 13 more classes in this area
Blood & clotting
30.1%Parenteral Iron Replacement12.9%Iron sucrose100%Part B, office-administered≥72 patientsIron, parenteral preparations10.3%Ferric carboxymaltose100%Part B, office-administered≥21 patients+ 3 more classes in this area
Metabolism & gastrointestinal
8.2%Substance P/Neurokinin-1 Receptor Antagonist6.7%Aprepitant100%Part B, office-administered≥44 patientsSerotonin-3 Receptor Antagonist1.3%Palonosetron hcl63%Ondansetron hydrochloride34%Ondansetron Odt2%Ondansetron Hcl1%Part D + Part B≥60 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Monk, MD
Florida Cancer Specialists & Research Institute
Bradford Perez, MD
Florida Cancer Specialists & Research Institute
Cesar Perez Batista, MD
Florida Cancer Specialists & Research Institute
Manish Patel, MD
Florida Cancer Specialists & Research Institute
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”